[go: up one dir, main page]

AR004498A1 - Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion - Google Patents

Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion

Info

Publication number
AR004498A1
AR004498A1 ARP960103399A AR10339996A AR004498A1 AR 004498 A1 AR004498 A1 AR 004498A1 AR P960103399 A ARP960103399 A AR P960103399A AR 10339996 A AR10339996 A AR 10339996A AR 004498 A1 AR004498 A1 AR 004498A1
Authority
AR
Argentina
Prior art keywords
procedure
preparation
pharmaceutical compositions
compositions containing
aminophosphonate
Prior art date
Application number
ARP960103399A
Other languages
English (en)
Original Assignee
Symphar Sa
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphar Sa, Smithkline Beecham Plc filed Critical Symphar Sa
Publication of AR004498A1 publication Critical patent/AR004498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen componentes de aminofosfonato sustituídos en alfa con grupos fenol de fórmula (I) que tienen actividad de disminución de la lipoproteína(a). Se describen además composiciones farmacéuticas que los contienen, el uso de los mismos y unprocedimiento para su preparación.
ARP960103399A 1995-06-30 1996-06-28 Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion AR004498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH01920/95A CH690264A5 (fr) 1995-06-30 1995-06-30 Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.

Publications (1)

Publication Number Publication Date
AR004498A1 true AR004498A1 (es) 1998-12-16

Family

ID=4221681

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103399A AR004498A1 (es) 1995-06-30 1996-06-28 Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion

Country Status (27)

Country Link
US (2) US6060464A (es)
EP (1) EP0835116A1 (es)
JP (1) JPH11508576A (es)
KR (1) KR19990028542A (es)
CN (1) CN1113654C (es)
AP (1) AP778A (es)
AR (1) AR004498A1 (es)
AU (1) AU705206B2 (es)
BG (1) BG102215A (es)
BR (1) BR9609653A (es)
CA (1) CA2225391A1 (es)
CH (1) CH690264A5 (es)
CZ (1) CZ422097A3 (es)
EA (1) EA199800106A1 (es)
HU (1) HUP9901684A3 (es)
IL (1) IL122717A0 (es)
MA (1) MA24340A1 (es)
MX (1) MX9800189A (es)
NO (1) NO976128L (es)
NZ (1) NZ312696A (es)
OA (1) OA10554A (es)
PL (1) PL187024B1 (es)
SK (1) SK178397A3 (es)
TR (1) TR199701700T1 (es)
TW (1) TW413681B (es)
WO (1) WO1997002037A1 (es)
ZA (1) ZA965505B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9626615D0 (en) * 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) * 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) * 1996-12-20 1997-02-05 Symphar Sa Novel compounds
DE19748659A1 (de) * 1997-11-04 1999-05-06 Hoechst Ag Aminophosphoniumgruppen enthaltende vernetzte Copolymere für medizinische Verwendungen
US6017918A (en) * 1998-08-06 2000-01-25 Warner-Lambert Company Phenyl glycine compounds and methods of treating atherosclerosis and restenosis
US6284795B1 (en) 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
AU775885B2 (en) 1999-10-27 2004-08-19 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
AU2001235466B2 (en) 2000-02-16 2004-04-22 Glaxo Group Limited Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
AU2001294792B2 (en) * 2000-09-27 2006-12-14 Ilex Products, Inc. Alpha-substituted beta-aminoethyl phosphonates
US20030114421A1 (en) * 2000-09-27 2003-06-19 Phan Hieu Trung Alpha-substituted beta-aminoethyl phosphonate derivatives
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0025849D0 (en) * 2000-10-23 2000-12-06 Smithkline Beecham Plc Novel compounds
US20050124581A1 (en) * 2002-02-11 2005-06-09 Phan Hieu T. Alpha-substituted heteroarylalkyl phosphonate derivatives
EP1504013A4 (en) * 2002-05-11 2006-05-03 Ilex Products Inc USE OF HYDROXYPHOSPHONATES AND PHOSPHONOPHOSPHATES AS MODULATORS OF APOLIPOPROTEIN E
EP1534679A4 (en) * 2002-08-30 2007-06-06 Biostratum Inc INHIBITORS OF POST-AMADORI ADVANCED GLYCATION ENDPRODUCTS
CA2820408C (en) 2010-12-06 2018-03-06 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
JP2014521611A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド Ｌｐ−ＰＬＡ２阻害剤としての２，３−ジヒドロイミダゾ［１，２−ｃ］ピリミジン−５（１Ｈ）−オン化合物の使用
AU2012300841C1 (en) 2011-09-01 2016-02-18 Glaxo Group Limited Novel crystal form
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
WO2014114694A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2021089032A1 (zh) 2019-11-09 2021-05-14 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683996A5 (fr) * 1992-03-05 1994-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et compositions pharmaceutiques les contenant.
DE4433244A1 (de) * 1994-09-19 1996-03-28 Hoechst Ag Aminomethylphosphon- und Aminomethylphosphinsäure-Derivate und deren Verwendung zur Behandlung von degenerativen Gelenkserkrankungen

Also Published As

Publication number Publication date
CH690264A5 (fr) 2000-06-30
EA199800106A1 (ru) 1998-08-27
AP9701160A0 (en) 1998-01-31
TR199701700T1 (xx) 1998-03-21
MA24340A1 (fr) 1998-07-01
PL187024B1 (pl) 2004-04-30
CZ422097A3 (cs) 1998-10-14
HUP9901684A2 (hu) 1999-09-28
CN1113654C (zh) 2003-07-09
PL324341A1 (en) 1998-05-25
NZ312696A (en) 1999-10-28
AU705206B2 (en) 1999-05-20
AU6418596A (en) 1997-02-05
US6060464A (en) 2000-05-09
EP0835116A1 (en) 1998-04-15
TW413681B (en) 2000-12-01
SK178397A3 (en) 1998-06-03
MX9800189A (es) 1998-04-30
CA2225391A1 (en) 1997-01-23
BR9609653A (pt) 1999-12-21
BG102215A (en) 1998-09-30
CN1193913A (zh) 1998-09-23
HUP9901684A3 (en) 2000-04-28
NO976128D0 (no) 1997-12-29
OA10554A (en) 2002-05-29
NO976128L (no) 1998-02-10
KR19990028542A (ko) 1999-04-15
IL122717A0 (en) 1998-08-16
JPH11508576A (ja) 1999-07-27
AP778A (en) 1999-10-29
WO1997002037A1 (en) 1997-01-23
US6660724B1 (en) 2003-12-09
ZA965505B (en) 1998-03-30

Similar Documents

Publication Publication Date Title
AR004498A1 (es) Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
MX9204354A (es) Compuestos heterociclicos de 5 miembros, procedimiento para prepararlos y composiciones farmaceuticas que los contienen.
CU23393A3 (es) Compuestos inhibidores de la raf kinasa y composiciones farmacéuticas que los contienen
ES2076688T3 (es) Derivados de 2-hidroxi-2-feniletilamina utiles como agonistas de beta-3-adrenoceptores.
BR9713704A (pt) Ceto-benzamida, uso da mesma, e, preparação de droga
ES548168A0 (es) Procedimiento para preparar composiciones de uso cosmetico o farmaceutico a base de unas esferulas lipidicas que contienen un polimero de poliamida.
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
MX9100317A (es) Nuevos compuestos de beta-lactama,procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
MX9204844A (es) Derivados de benzodioxano, procedimiento para su preparacion composiciones farmaceuticas que los contienen.
MX9102500A (es) Compuestos de bifenilio, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2158284T3 (es) Metil-fenil-oxazolidinonas quirales.
ES2098505T3 (es) Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
AR033957A1 (es) Nuevos compuestos
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9303123A (es) Ciclopentano-y-penteno-beta-aminoacidos, procedimiento para su preparacion y medicamentos que los contienen.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2077354T3 (es) Derivados de 2-hidroxi-2-feniletilamina utiles como agonistas de beta-3-adrenoceptores.
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
ES2021515A6 (es) Procedimiento para la preparacion de compuestos derivados de isotiazolo-piridona azetidinil substituidos.
MX9200996A (es) Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9207264A (es) Compuestos de sulfonimidamida, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen